Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
Anaerobe|August 22, 2017
Fusobacterium nucleatum detected simultaneously in a pyogenic liver abscess and advanced sigmoid colon cancerRyuta Shigefuku, Tsunamasa Watanabe, Yuki Kanno, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|November 24, 2021
Prediction of esophagogastric varices associated with oxaliplatin administrationYosuke Satta, Ryuta Shigefuku, Tsunamasa Watanabe, et al.
Scientific Reports|May 4, 2022
Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver diseaseTadamichi Kawano, Masanori Atsukawa, Akihito Tsubota, et al.
Immunity|January 6, 2015
The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virusSeiichi Sato, Kai Li, Takeshi Kameyama, et al.
Plos One|February 14, 2022
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis BYoshihito Nagura, Kentaro Matsuura, Etsuko Iio, et al.
International Journal of Molecular Sciences|September 21, 2016
Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C VirusRyuta Shigefuku, Hideaki Takahashi, Hiroyasu Nakano, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|May 9, 2022
Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapyHidenori Toyoda, Satoshi Yasuda, Akio Moriya, et al.
Journal of Medical Virology|June 23, 2016
Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevirHiroki Ikeda, Tsunamasa Watanabe, Chiaki Okuse, et al.
Journal of Gastroenterology|November 15, 2017
Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infectionHiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, et al.
Journal of Gastroenterology|October 21, 2017
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infectionHiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, et al.
Pageof 12